In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reviewing Five Years of Big Pharma's Biotech Acquisitions

Executive Summary

A review of the past five years' significant ($100mm or greater) pharma-biotech acquisitions among the industry's largest players illustrates Big Pharma's diverging M&A strategies, and why there's more to come. We examine who's buying and how much has been spent, and take a look at who has succeeded in getting value (and pipeline) for money.
Advertisement

Related Content

Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Big Pharma's Year of Big Layoffs
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007
Are Share Buybacks a Wise Investment for Biopharma
Activist Shareholders Complicate Buyout Math
Pfizer Deal Highlights Bristol's Biotech Swagger
The Heyday of Biotech Dealmaking
CEO Interview: AstraZeneca's David Brennan
Share the Wealth? No Thanks
Behind Scios-J&J: No Groundswell for M&A

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel